CEO Daniel Gold told BioWorld Today that MEI Pharma Inc. will fiddle with dosing and schedules in a new phase II study with pracinostat for myelodysplastic syndromes (MDS) as Helsinn Group starts a phase III trial testing the histone deacetylase (HDAC) inhibitor against acute myeloid leukemia (AML) under the terms of a deal worth up to $464 million.